Recombinant Human CTSK Protein，His

CTSK (Cathepsin K) is a lysosomal cysteine protease predominantly expressed in osteoclasts, the cells responsible for bone resorption. The enzyme plays a critical role in bone metabolism by breaking down collagen and other extracellular matrix proteins, contributing to the maintenance of bone health and homeostasis. Dysregulation of CTSK activity is associated with various bone disorders, including osteoporosis, rheumatoid arthritis, and Paget's disease, where excessive bone resorption leads to weakened bone structure. Due to its pivotal role in osteoclast function and bone remodeling, CTSK has become a significant target for therapeutic interventions aimed at mitigating bone loss. Research into recombinant CTSK (rCTSK) has gained traction in recent years, facilitating investigations into its enzymatic properties, mechanism of action, and potential as a biomarker for bone diseases. The production of rCTSK using recombinant DNA technology allows for the generation of large quantities of the enzyme, enabling detailed studies of its biological functions and interactions with other proteins. Furthermore, by employing rCTSK in preclinical models, researchers are exploring its applications in drug development, including inhibitors that could slow down bone resorption and provide novel treatment options for patients suffering from osteoclast-related diseases. Overall, the study of CTSK and its recombinant form not only enhances our understanding of bone physiology but also holds promise for advancing therapeutic strategies in osteoporosis and other related conditions.